Skip to main content
. 2018 Dec 13;5(2):e184475. doi: 10.1001/jamaoncol.2018.4475

Figure 3. Best Percentage Change From Baseline in Sum of Longest Diameters and Best Overall Response in Patients With Estrogen Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer.

Figure 3.

A, PIK3CA-altered tumors. Forty-three patients excluded from missing best percentage change from baseline because of no postbaseline assessment or nonmeasurable lesion at baseline. B, PIK3CA-wild-type tumor. Seventeen patients excluded from missing best percentage change from baseline because of no postbaseline assessment or nonmeasurable lesion at baseline. Data cutoff point was March 22, 2017. CR indicates complete response; mTOR, mammalian target of rapamycin; PD, progressive disease; PR, partial response; SD, stable disease; and UNK, unknown. The dotted lines correspond to a +20% and −30% change from baseline.

aIncludes 3 patients with human epidermal growth factor receptor 2–positive, estrogen receptor–positive, locally advanced or metastatic breast cancer.